Article
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.
Cancer discovery - 1 May 2014
Abdel-Wahab Omar, Klimek Virginia M, Gaskell Alisa A, Viale Agnes, Cheng Donavan, Kim Eunhee, Rampal Raajit, Bluth Mark, Harding James J, Callahan Margaret K, Merghoub Taha, Berger Michael F, Solit David B, Rosen Neal, Levine Ross L, Chapman Paul B
Abstract excerpt
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAF(V600)-mutant melanoma but activates extracellular signal-regulated kinase (ERK) signaling in RAS-mutant cells. In a patient with a BRAF(V600K)-mutant melanoma responding to vemurafenib, we observed accelerated progression of a previously unrecognized NRAS-mutant leukemia. We hypothesized that combining vemurafenib with a MAP-ERK kinase (MEK)...
Topics
- Aged
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Azetidines
- Cell Line, Tumor
- Cell Proliferation
- DNA, Neoplasm
- Drug Administration Schedule
- GTP Phosphohydrolases